The European Patent Office has indicated it favors the University of California's argument that its discovery covers CRISPR use in both prokaryotic and eukaryotic systems, boosting UC's legal position and that of the companies which have licensed its genome editing patents.
UC and its commercial licensees have been fighting the Broad Institute of Cambridge, Massachusetts and its ally Editas Medicine...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
